Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epirubicin-loaded CalliSpheres microsphere TACE for hepatocellular carcinoma
ChiCTR1900022968Phase 4Not yet recruiting
- Sponsor
- Union Hospital
- Start
- May 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of epirubicin in hepatocellular carcinoma (HCC) and liver cancer, sponsored by Union Hospital. Primary endpoints: progression-free survival and serious adverse events. Planned start May 2019; status: not yet recruiting.
02
Drugs
epirubicin
03
Conditions
hepatocellular carcinoma (HCC)liver cancer
Beyond the preview
Go deeper on ChiCTR1900022968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022968.